These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 22642028)

  • 1. [Rapid postprandial blood glucose control: indications for better cardiovascular protection in the diabetic patient].
    MMW Fortschr Med; 2012 Apr; 154(6):34-5. PubMed ID: 22642028
    [No Abstract]   [Full Text] [Related]  

  • 2. [Blood pressure control in patients with diabetes mellitus. Focus on postprandial blood glucose values and cardiovascular risk].
    MMW Fortschr Med; 2012 Feb; 154(3):82-3. PubMed ID: 22458177
    [No Abstract]   [Full Text] [Related]  

  • 3. [Dangerous blood glucose peaks. Vascular damage even before diabetes].
    MMW Fortschr Med; 2003 Sep; 145(35-36):53. PubMed ID: 14584214
    [No Abstract]   [Full Text] [Related]  

  • 4. Effects of mealtime insulin aspart and bedtime neutral protamine Hagedorn insulin on postprandial coagulation and fibrinolysis in patients with type 2 diabetes.
    Bladbjerg EM; Henriksen JE; Akram S; Gram J
    Diabetes Obes Metab; 2012 May; 14(5):447-53. PubMed ID: 22151836
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Revised blood pressure goals and no elevated glucose readings in between].
    MMW Fortschr Med; 2005 Dec; 147(51-52):72. PubMed ID: 16402718
    [No Abstract]   [Full Text] [Related]  

  • 6. [Postprandial hyperglycemia. Cardiovascular risks and new therapeutic strategies].
    Sjöholm A
    Lakartidningen; 2001 Feb; 98(9):937-40. PubMed ID: 11292972
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Acarbose--an effective drug for the prevention of type 2 diabetes and cardiovascular diseases?].
    Laakso M
    Duodecim; 2003; 119(20):1921-3. PubMed ID: 14639996
    [No Abstract]   [Full Text] [Related]  

  • 8. [Is an intensive glycaemic control beneficial in diabetes type 2?].
    Martin S
    Dtsch Med Wochenschr; 2011 Sep; 136(39):1940. PubMed ID: 21948602
    [No Abstract]   [Full Text] [Related]  

  • 9. [Clinical advances in diabetes].
    Martin S; Scherbaum WA
    Dtsch Med Wochenschr; 2006 Jun; 131(25-26):1461-2. PubMed ID: 16794976
    [No Abstract]   [Full Text] [Related]  

  • 10. Coverage of postprandial blood glucose excursions with inhaled technosphere insulin in comparison to subcutaneously injected regular human insulin in subjects with type 2 diabetes.
    Rave K; Heise T; Pfützner A; Boss AH
    Diabetes Care; 2007 Sep; 30(9):2307-8. PubMed ID: 17586744
    [No Abstract]   [Full Text] [Related]  

  • 11. Treating postprandial hyperglycemia does not appear to delay progression of early type 2 diabetes: the Early Diabetes Intervention Program.
    Kirkman MS; Shankar RR; Shankar S; Shen C; Brizendine E; Baron A; McGill J
    Diabetes Care; 2006 Sep; 29(9):2095-101. PubMed ID: 16936159
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Incretin therapy for type 2 diabetes mellitus.
    Klonoff DC
    Adv Ther; 2010 Dec; 27(12):881-94. PubMed ID: 20978879
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Diversity in diabetes: the role of insulin aspart.
    Heller S; McCance DR; Moghissi E; Nazeri A; Kordonouri O
    Diabetes Metab Res Rev; 2012 Jan; 28(1):50-61. PubMed ID: 21695769
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Early and intensive therapy for management of hyperglycemia and cardiovascular risk factors in patients with type 2 diabetes.
    Dailey G
    Clin Ther; 2011 Jun; 33(6):665-78. PubMed ID: 21704233
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Role of postprandial hyperglycemia in cardiovascular disease.
    Fava S
    Expert Rev Cardiovasc Ther; 2008 Jul; 6(6):859-72. PubMed ID: 18570623
    [TBL] [Abstract][Full Text] [Related]  

  • 16. TAK-875, an orally available G protein-coupled receptor 40/free fatty acid receptor 1 agonist, enhances glucose-dependent insulin secretion and improves both postprandial and fasting hyperglycemia in type 2 diabetic rats.
    Tsujihata Y; Ito R; Suzuki M; Harada A; Negoro N; Yasuma T; Momose Y; Takeuchi K
    J Pharmacol Exp Ther; 2011 Oct; 339(1):228-37. PubMed ID: 21752941
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Glycemic targets for patients with type 2 diabetes mellitus.
    Hamnvik OP; McMahon GT
    Mt Sinai J Med; 2009 Jun; 76(3):227-33. PubMed ID: 19421966
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibition of postprandial hyperglycemia by acarbose is a promising therapeutic strategy for the treatment of patients with the metabolic syndrome.
    Yamagishi S; Nakamura K; Takeuchi M
    Med Hypotheses; 2005; 65(1):152-4. PubMed ID: 15893133
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of different pharmacological formulations of gliclazide on postprandial hyperglycaemia.
    Bardini G; Mannucci E; Rotella CM
    Diabet Med; 1998 Aug; 15(8):706. PubMed ID: 9702477
    [No Abstract]   [Full Text] [Related]  

  • 20. Reduction of cardiovascular morbidity and mortality in type 2 diabetes. A rational approach to hypoglycemic therapy.
    Spallarossa P; Barsotti A; Cordera R; Ghigliotti G; Maggi D; Brunelli C
    J Endocrinol Invest; 2004 May; 27(5):485-95. PubMed ID: 15279085
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.